Posters

      Assessing the impact of switching to the Tobacco Heating System on cardiovascular disease: Translating basic science into clinical benefit

      Baker, G.; de la Bourdonnaye, G.; Elamin, A.; Goujon, C.; Haziza, C.; Heremans, A.; Hoeng, J.; Ivanov, N.; Luedicke, F.; Maeder, S.; Phillips, B.; Picavet, P.; Pouly, S.; Poussin, C.; Pratte, P.; Tran, C. T.; Vanscheeuwijck, P.; Peitsch, M.

      Conference date
      Dec 11, 2020
      Conference name

      68th Annual Scientific Meeting of the cardiac society of Australia and New Zealand
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

      Pre-clinical Toxicology

      Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

      Pre-clinical Toxicology

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.